HARROW, INC. (HROW): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

HARROW, INC. (HROW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer

Original reporting
Published Sep 4, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$HROW
Neutral
medium confidence
Mentioned
$HROW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HROWNeutralLow
01

Why it matters

The filing provides the first public notice of the leadership change, which may influence short‑term stock movement.

02

Market read

Primary corporate action filing with modest trading relevance.

03

What to watch

Potential impact on internal controls and future audit outcomes.

Relevance 6/10Novelty 5/10Timing: effective September 4, 2026

Background

Harrow, Inc. (HROW) filed an 8‑K announcing an executive departure and internal appointment.

Company-level read

Ticker impact

$HROWNeutralMedium confidence
Context

SEC Form 8‑K reports the departure of CAO Randall Pollard and appointment of CFO Andrew Boll as principal accounting officer.

Expected impact

Minor short‑term volatility expected; no clear directional bias.

Evidence & confidence

Executive turnover is material for governance but no compensation change or strategic shift disclosed.

Market effects

Limited impact on the broader sector; similar filings are routine.

No regional effect beyond Harrow's shareholder base.

Not globally relevant.

Counterpoint

The change could signal deeper governance issues not yet disclosed.

Key entities

  • Harrow, Inc.

    US‑listed firm reporting the executive change.

  • Randall E. Pollard

    Departing Chief Accounting Officer.

  • Andrew R. Boll

    Current President & CFO appointed as principal accounting officer.

Related articles

$HROWMed

Harrow Q3 Earnings Call Highlights

Harrow reported Q3 revenue of $99.3M, with VEVYE contributing $39.7M (up 35% sequentially). IHEEZO and TRIESENCE unit demand rose 21% and 37% sequentially, respectively. The QUELL study missed its primary endpoint but showed lower pain scores for IHEEZO. Harrow plans to submit a new drug application for G-MELT and is in discussions regarding licensing agreements.

$HROWHighAI 8/10

Harrow Q3 2026 slides: record revenue, product portfolio expansion

Harrow (HROW) reported Q3 2026 revenue of $99.3M, up 41% sequentially and 39% YoY, with adjusted EBITDA at $21.2M. Key products VEVYE, IHEEZO, and TRIESENCE drove growth. The company reaffirmed FY 2026 revenue guidance of $350M-$365M but lowered adjusted EBITDA outlook. Harrow expanded its product portfolio and commercial infrastructure, acquiring TYRVAYA in October 2026.

$HROWMed

Harrow Announces Third Quarter 2026 Financial Results

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Harrow Announces Third Quarter 2026 Financial Results Third Quarter 2026 and Selected Highlights: • Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year • Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total r